Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: A case-control study

Annals of Neurology

Volumn 80, Issue 4, 2016, Pages 566-580

  Meyer Sauteur, Patrick M ^a,b   Huizinga, Ruth ^c   Tio Gillen, Anne P ^c   Roodbol, Joyce ^a,c   Hoogenboezem, Theo ^a   Jacobs, Enno ^d   van Rijn, Monique ^e   van der Eijk, Annemiek A ^c   Vink, Cornelis ^a,f   de Wit, Marie Claire Y ^a   van Rossum, Annemarie M C ^a   Jacobs, Bart C ^c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CODEINE; GALACTOCEREBROSIDE ANTIBODY; GALACTOSYLCERAMIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD1A ANTIBODY; GANGLIOSIDE GD1B ANTIBODY; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; GANGLIOSIDE GM2; GANGLIOSIDE GM2 ANTIBODY; GANGLIOSIDE GQ 1B; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHYLPREDNISOLONE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CRANIAL NEUROPATHY; CROSS REACTION; DISEASE ASSOCIATION; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NEUROLOGIC DISEASE; PLASMA EXCHANGE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; COMPLICATION; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY; MIDDLE AGED; MYCOPLASMOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; CROSS REACTIONS; FEMALE; GALACTOSYLCERAMIDES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; YOUNG ADULT;

EID: 84983487426     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24755     Document Type: Article

References (45)

1. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469–482.
2. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110–1115.
3. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979;139:681–687.
4. Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol 2009;41:159–166.
5. Meyer Sauteur PM, Jacobs BC, Spuesens EB, et al. Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS Pathog 2014;10:e1003983.
6. Hao Q, Saida T, Kuroki S, et al. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 1998;81:116–126.
7. Sinha S, Prasad KN, Jain D, et al. Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study. Clin Microbiol Infect 2007;13:334–337.
8. Caudie C, Quittard Pinon A, Taravel D, et al. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients. J Neurol 2011;258:1958–1964.
9. Sharma MB, Chaudhry R, Tabassum I, et al. The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. J Infect Dev Ctries 2011;5:459–464.
10. Ang CW, Tio-Gillen AP, Groen J, et al. Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome. J Neuroimmunol 2002;130:179–183.
11. Kusunoki S, Chiba A, Hitoshi S, et al. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995;18:409–413.
12. Nishimura M, Saida T, Kuroki S, et al. Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1996;140:91–95.
13. Kusunoki S, Shiina M, Kanazawa I. Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 2001;57:736–738.
14. Susuki K, Odaka M, Mori M, et al. Acute motor axonal neuropathy after Mycoplasma infection: evidence of molecular mimicry. Neurology 2004;62:949–956.
15. Coetzee T, Suzuki K, Popko B. New perspectives on the function of myelin galactolipids. Trends Neurosci 1998;21:126–130.
16. Fry JM, Weissbarth S, Lehrer GM, Bornstein MB. Cerebroside antibody inhibits sulfatide synthesis and myelination and demyelinates in cord tissue cultures. Science 1974;183:540–542.
17. Saida T, Saida K, Dorfman SH, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979;204:1103–1106.
18. Kusunoki S, Takizawa H, Kanazawa I. Infection by Mycoplasma pneumoniae induces serum antibody against Gal-C. Muscle Nerve 1996;19:257–258.
19. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):s21–s24.
20. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37–44.
21. Ang CW, Jacobs BC, Brandenburg AH, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology 2000;54:1453–1458.
22. Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol 2007;188:69–73.
23. Kuijf ML, Samsom JN, van Rijs W, et al. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol 2010;185:748–755.
24. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750–753.
25. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103–1109.
26. Chalker VJ, Pereyre S, Dumke R, et al. International Mycoplasma pneumoniae typing study: interpretation of M. pneumoniae multilocus variable-number tandem-repeat analysis. New Microbes New Infect 2015;7:37–40.
27. Brandsema P, Dijkstra F, Euser S, et al. Annual report surveillance respiratory infectious diseases 2011. Project group respiratory infections. RIVM Briefrapport 201041001/2012.
28. Lenglet A, Herrador Z, Magiorakos AP, et al. Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill 2012;17:pii=20075.
29. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013;10:e1001444.
30. Jacobs E, Ehrhardt I, Dumke R. New insights in the outbreak pattern of Mycoplasma pneumoniae. Int J Med Microbiol 2015;305:705–708.
31. Huizinga R, van den Berg B, van Rijs W, et al. Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome. Ann Neurol 2015;78:343–354.
32. Christie LJ, Honarmand S, Yagi S, et al. Anti-galactocerebroside testing in Mycoplasma pneumoniae-associated encephalitis. J Neuroimmunol 2007;189:129–131.
33. Samukawa M, Hirano M, Tsugawa J, et al. Refractory acute disseminated encephalomyelitis with anti-galactocerebroside antibody. Neurosci Res 2012;74:284–289.
34. Samukawa M, Hamada Y, Kuwahara M, et al. Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody. J Neurol Sci 2014;337:55–60.
35. van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology 2013;80:1650–1654.
36. Miyachi A, Miyazaki A, Shingu Y, et al. Synthesis and absolute structures of Mycoplasma pneumoniae beta-glyceroglycolipid antigens. Carbohydr Res 2009;344:36–43.
37. Taylor JJ, Jenkins MK, Pape KA. Heterogeneity in the differentiation and function of memory B cells. Trends Immunol 2012;33:590–597.
38. van Riet E, Wuhrer M, Wahyuni S, et al. Antibody responses to Ascaris-derived proteins and glycolipids: the role of phosphorylcholine. Parasite Immunol 2006;28:363–371.
39. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001;7:899–905.
40. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192–196.
41. Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 2010;75:1439–1447.
42. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123–1129.
43. Meyer Sauteur PM, Unger WWJ, Nadal D, et al. Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol 2016;7:329.
44. Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263–268.
45. van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589–594.